Contributions
Abstract: EP1681
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Compliance to therapy has been associated with a reduced risk of relapse, reduced healthcare resource utilization and improved health-related quality-of-life in patients with multiple sclerosis (MS).
Objective: To assess compliance and discontinuation rates with Disease-Modifying Therapies (DMTs) in Canadian patients with Relapsing-Remitting MS (RRMS).
Methods: In this Canadian retrospective claims analysis based on Rx Dynamics® data from IMS Health Canada Inc., patients had ≥1 prescription filled for each DMT (oral: fingolimod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were considered compliant if the medication possession ratio (MPR) was ≥80%. Discontinuation rates were calculated based on patients who stopped therapy (60 day window) or who were switched to another DMT. Compliance and discontinuation rates were collected 6, 12 and 24-month periods (cohorts from 2013-2017, rolling 36 months total).
Results: Compliance and discontinuation data was collected after 6 month (n=12543, n=9460 respectively), 12 month (n=7665, n=7234) and 24 month (n=6047, n=6030) periods. The percentage of patients deemed compliant after 6, 12- and 24-months across Canada was higher for fingolimod (75%, 76%, 71% respectively), compared to natalizumab (72%, 73%, 56%), DMF (71%, 68%, 55%), and BRACE (52%, 46%, 35%) and comparable to teriflunomide (76%, 77%, 68%). Patients on fingolimod had the lowest discontinuation rate after 6, 12 and 24-month periods (26%, 25%, 29% respectively) compared to: BRACE (48%, 35%, and 55%); natalizumab (34%, 29%, and 49%) and DMF (31%, 30% and 43%); and similar to teriflunomide (26%, 25%, 31%).
Conclusions: The percentage of patients deemed compliant and treated with fingolimod was higher than for other DMTs but was similar to teriflunomide. Unlike other DMTs, the discontinuation rate with fingolimod did not significantly increase and the compliance rate with fingolimod remained stable over the 24-month period. The discontinuation rate of fingolimod was lower compared to other DMTs at all time points and was similar to teriflunomide. This analysis provides insight into short and medium term compliance and discontinuation of DMTs in a Canadian real-world setting. These findings may inform MS management strategies which may lead to improved clinical and economic outcomes.
Disclosure:
Pierre Duquette: has received honoraria for advisory boards, for CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono and Teva Neurosience. He has taken part in Investigator-initiated trials funded by Novartis, Biogen-Idec, Genzyme and EMD Serono and has received funding from peer-reviewed agencies such as the Canadian Institutes for Health Research (CIHR) and the MS Society of Canada.
Michael Yeung: has received honoraria for consultation fees from EMD-Serono, Genzyme and Novartis, and the Canadian Agency for Drugs and Technologies in Health (CADTH/Health Canada), and research support from Biogen-Idec, Genzyme, Hoffmann-La Roche, Novartis, and Teva Canada Innovation.
Robyn Schecter: is an employee of Novartis Pharmaceuticals Canada Inc.
Paola Haddad: is an employee of Novartis Pharmaceuticals Canada Inc.
Katherine Jobin Gervais: is an employee of Novartis Pharmaceuticals Canada Inc.
Hamid Reza Nakhaipour: is an employee of Novartis Pharmaceuticals Canada Inc.
Findings based in part on data licensed from IMS Health Canada Inc. All Rights Reserved.
Abstract: EP1681
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
Background: Compliance to therapy has been associated with a reduced risk of relapse, reduced healthcare resource utilization and improved health-related quality-of-life in patients with multiple sclerosis (MS).
Objective: To assess compliance and discontinuation rates with Disease-Modifying Therapies (DMTs) in Canadian patients with Relapsing-Remitting MS (RRMS).
Methods: In this Canadian retrospective claims analysis based on Rx Dynamics® data from IMS Health Canada Inc., patients had ≥1 prescription filled for each DMT (oral: fingolimod, dimethyl fumarate (DMF), teriflunomide; injectable (BRACE): interferon beta-1a, interferon beta-1b, glatiramer acetate; infusible: natalizumab). Patients were considered compliant if the medication possession ratio (MPR) was ≥80%. Discontinuation rates were calculated based on patients who stopped therapy (60 day window) or who were switched to another DMT. Compliance and discontinuation rates were collected 6, 12 and 24-month periods (cohorts from 2013-2017, rolling 36 months total).
Results: Compliance and discontinuation data was collected after 6 month (n=12543, n=9460 respectively), 12 month (n=7665, n=7234) and 24 month (n=6047, n=6030) periods. The percentage of patients deemed compliant after 6, 12- and 24-months across Canada was higher for fingolimod (75%, 76%, 71% respectively), compared to natalizumab (72%, 73%, 56%), DMF (71%, 68%, 55%), and BRACE (52%, 46%, 35%) and comparable to teriflunomide (76%, 77%, 68%). Patients on fingolimod had the lowest discontinuation rate after 6, 12 and 24-month periods (26%, 25%, 29% respectively) compared to: BRACE (48%, 35%, and 55%); natalizumab (34%, 29%, and 49%) and DMF (31%, 30% and 43%); and similar to teriflunomide (26%, 25%, 31%).
Conclusions: The percentage of patients deemed compliant and treated with fingolimod was higher than for other DMTs but was similar to teriflunomide. Unlike other DMTs, the discontinuation rate with fingolimod did not significantly increase and the compliance rate with fingolimod remained stable over the 24-month period. The discontinuation rate of fingolimod was lower compared to other DMTs at all time points and was similar to teriflunomide. This analysis provides insight into short and medium term compliance and discontinuation of DMTs in a Canadian real-world setting. These findings may inform MS management strategies which may lead to improved clinical and economic outcomes.
Disclosure:
Pierre Duquette: has received honoraria for advisory boards, for CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono and Teva Neurosience. He has taken part in Investigator-initiated trials funded by Novartis, Biogen-Idec, Genzyme and EMD Serono and has received funding from peer-reviewed agencies such as the Canadian Institutes for Health Research (CIHR) and the MS Society of Canada.
Michael Yeung: has received honoraria for consultation fees from EMD-Serono, Genzyme and Novartis, and the Canadian Agency for Drugs and Technologies in Health (CADTH/Health Canada), and research support from Biogen-Idec, Genzyme, Hoffmann-La Roche, Novartis, and Teva Canada Innovation.
Robyn Schecter: is an employee of Novartis Pharmaceuticals Canada Inc.
Paola Haddad: is an employee of Novartis Pharmaceuticals Canada Inc.
Katherine Jobin Gervais: is an employee of Novartis Pharmaceuticals Canada Inc.
Hamid Reza Nakhaipour: is an employee of Novartis Pharmaceuticals Canada Inc.
Findings based in part on data licensed from IMS Health Canada Inc. All Rights Reserved.